news
Opdivo® and Yervoy® combo increases mesothelioma survival
Opdivo and Yervoy displayed a 23 percent survival rate at three years compared to 15 percent with chemotherapy, Phase III trial shows.
List view / Grid view
Opdivo (nivolumab)
news
EU approves Opdivo plus Yervoy for colorectal cancer
The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for certain metastatic colorectal cancers after a trial found the combination meaningfully improved response rates.
article
Antibody-drug conjugates: challenges, solutions and future potential
The ability to precisely direct powerful therapeutics not only makes treatments more effective, but also prevents debilitating side effects. Here, Dave Elder and Stacey Treichler highlight the great potential of antibody-drug conjugates (ADCs) for improved treatment of oncology indications and beyond.
news
EC approves Cabometyx® and Opdivo® combination for advanced renal cell carcinoma
The combination was approved on Phase III trial results which show it doubled progression-free survival and reduced risk of death by 40 percent, compared to standard of care.
news
EC approves Opdivo for treatment of oesophageal squamous cell carcinoma
The European Commission has approved Opdivo (nivolumab) to treat oesophageal squamous cell carcinoma after studies showed its clinical benefits compared to chemotherapy alone.
news
NICE rules nivolumab is not cost effective for use on NHS
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
news
EMA releases results from February meeting, recommending two medicines
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
news
Keytruda overtakes Opdivo in Q3 sales to reach $3.1bn
Sales of Merck’s drug Keytruda have grown beyond those of Bristol-Myers Squibb’s Opdivo, to become the global leading PD-1 inhibitor.
article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
news
Metastatic melanoma treatment gets Breakthrough Therapy Designation
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
news
Rare melanoma type highly responsive to immunotherapy
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
news
Nivolumab superior to ipilimumab for adjuvant treatment of melanoma
Adjuvant nivolumab has been found to be more superior than ipilimumab in the standard of care in patients with surgically resected stage III/IV melanoma...
news
Nivolumab cuts relapse by one third compared to Ipilimumab
Alternative immunotherapy drug nivolumab is more effective than current standard of care in treating advanced melanoma after surgical removal of disease.
news
Novartis & Bristol-Myers Squibb to collaborate on cancer treatments
7 June 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist...
article
N is for Nivolumab
1 December 2016 | By Niamh Louise Marriott, Digital Editor
N is for Nivolumab - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...